Individuals with significant body weight to lose, typically those with a BMI that qualifies for GLP-1 therapy and who have 30% or more body weight to lose, may benefit from the more aggressive metabolic intervention this combination provides
(Sub cutaneous injections would be most sensible for patients to use and are the route most who self inject choose, myself included.) We need our doctors to get behind this movement so that they and the Practice nurses can be freed up from giving injections to those who can inject themselves
Tirzepatide has shown higher weight loss potential in clinical trials
This hormonal shift is similar to what many women experience during menopause, but can be much more abrupt and severe in the context of ovarian cancer
The goal of these programs is to provide members with support for long-term success
Ocular complications from GLP-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations Journal of the Chinese Medical Association